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2In 2005, an estimated 6,500 Iowans will die from cancer, 15 times
the number caused by auto fatalities. Cancer is second only to heart
disease as a cause of death. These projections are based upon
mortality data the State Health Registry of Iowa receives from the
Iowa Department of Public Health. The Registry has been recording
the occurrence of cancer in Iowa since 1973, and is one of fourteen
registries nationwide providing data to the National Cancer Institute.
With 2005 Cancer in Iowa the Registry makes a general report to the
public on the status of cancer. This report will focus on:
• a description of the Registry and its goals;
• cancer estimates for 2005;
• a special section on prostate cancer;
• brief summaries of research projects during 2005;
• a selected list of publications from 2004.
3The State Health Registry of Iowa
Cancer is a reportable disease as stated in the Iowa
Administrative Code. Cancer data are collected by
the State Health Registry of Iowa, located at The
University of Iowa in the College of Public Health’s
Department of Epidemiology. The staff includes
more than 50 people. Half of them, situated
throughout the state, regularly visit hospitals, clinics,
and medical laboratories in Iowa and neighboring
states to collect cancer data. A follow-up program
tracks more than 97 percent of the cancer survivors
diagnosed since 1973. This program provides regular
updates for follow-up and survival. The Registry
maintains the confidentiality of the patients,
physicians, and hospitals providing data.
In 2005 data will be collected on an estimated 15,800
new cancers among Iowa residents. Beginning with
2005 Cancer in Iowa, in situ cases of bladder cancer
are included in the estimates for bladder cancer,
to be in agreement with the definition of reportable
cases of the Surveillance, Epidemiology, and End
Results (SEER) Program of the National Cancer
Institute.
Since 1973 the Iowa Registry has been funded by the
SEER Program of the National Cancer Institute. Iowa
represents rural and midwestern populations and
provides data included in many NCI publications.
Beginning in 1990 about 5-10 percent of the Registry’s
annual operating budget has been provided by the
state of Iowa. Beginning in 2003, the University of
Iowa has also been providing cost-sharing funds.
The Registry also receives funding through grants
and contracts with university, state, and national
researchers investigating cancer-related topics.
During 2005, the Registry will respond to
300 requests for data, analyses, and cancer
cluster investigations.
The goals of the Registry are to:
• assemble and report measurements
of cancer incidence, survival and
mortality among Iowans;
• provide information on changes
over time in the extent of disease
at diagnosis, therapy, and patient
survival;
• promote and conduct studies designed
to identify factors relating
to cancer etiology, prevention
and control;
• respond to requests from individuals
and organizations in the state of
Iowa for cancer data and analyses;
• provide data and expertise for cancer
research activities and educational
opportunities.
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Cancer Projections for 2005
Estimated Number of New Cancers in Iowa for 2005
Estimated Number of Cancer Deaths in Iowa for 2005
In 2005, cancer will strike five out of every 1,000
Iowans. Cancer is the second leading cause of
death in Iowa, responsible for about 230 of every
1,000 deaths. Breast, colon & rectum, lung, and
prostate cancers will account for more than half
of all new cancers and cancer deaths.
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5New Cancers in Females
Type # of Cancers   % of Total
Breast 2250 28.8
Colon & Rectum 1080 13.8
Lung 920 11.8
Uterus 480 6.2
Non-Hodgkin Lymphoma 320 4.1
Skin Melanoma 280 3.6
Ovary 250 3.2
Bladder (invasive and noninvasive) 200 2.6
Leukemia 200 2.6
Thyroid 190 2.4
All Others 1630 20.9
Total 7800
New Cancers in Males
Type                 # of Cancers  % of Total
Prostate 2250 28.1
Lung 1150 14.4
Colon & Rectum 1000 12.5
Bladder (invasive and noninvasive) 540 6.8
Non-Hodgkin Lymphoma 320 4.0
Skin Melanoma 290 3.6
Leukemia 270 3.4
Kidney & Renal Pelvis 260 3.3
Oral Cavity 180 2.2
Pancreas 180 2.2
All Others 1560 19.5
Total 8000
Cancer Deaths in Females
Type                # of Cancers % of Total
Lung 730 23.2
Breast 440 14.0
Colon & Rectum 350 11.1
Pancreas 190 6.0
Ovary 170 5.4
Non-Hodgkin Lymphoma 140 4.5
Leukemia 130 4.1
Uterus 90 2.9
Brain 80 2.5
Multiple Myeloma 70 2.2
All Others 760 24.1
Total 3150
Cancer Deaths in Males
Type                # of Cancers % of Total
Lung 1020 30.4
Prostate 400 11.9
Colon & Rectum 350 10.4
Pancreas 160 4.8
Leukemia 160 4.8
Non-Hodgkin Lymphoma 150 4.5
Esophagus 120 3.6
Kidney & Renal Pelvis 110 3.3
Brain 90 2.7
Bladder 90 2.7
All Others 700 20.9
Total 3350
Fortunately for Iowans, the chances of being diagnosed with many types of cancer can be reduced
through positive health practices such as smoking cessation, physical exercise, healthful dietary habits,
and alcohol consumption in moderation. Early detection through self-examination and regular health
checkups can improve cancer survival.
Top 10 Types of Cancer in Iowa Estimated for 2005
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6The prostate is a gland in males that is located
between the bladder and the rectum. The normal
prostate gland is the size of a walnut and surrounds
the urethra, the tube that carries urine from the
bladder. Carcinoma of the prostate is the most
common tumor (excluding non-melanotic skin cancer)
in men in the United States, with 232,090 new cases
and 30,350 deaths expected in 2005. The disease is
histologically evident in as many as 34% of men in
their fifth decade and in up to 70% of men aged 80
years and older. Prostate cancer will be diagnosed in
almost one-fifth of US men during their lifetime, yet
only 3% of men will be expected to die of the disease.
Figure 1 shows the overall incidence and mortality
rates of prostate cancer in Iowa from 1973-2002.
We saw a 145% increase in incidence between 1973 and
1992, and a 27% decrease in incidence between 1992
and 2002. Causes of these trends are not totally clear
but have been largely attributed to increased aware-
ness of the disease and more early detection. Known
Prostate Cancer
risk factors for prostate cancer include age (high
prevalence in the elderly), race (excess in blacks),
and positive family history. Dietary factors and
agricultural exposures are still incompletely studied.
Between 1973 and 2002, mortality rates have fluctu-
ated much less than incidence rates. Compared to
the 1970s and 1980s, far fewer men diagnosed with
prostate cancer in the 1990s and thereafter have
been dying from this disease.
Figure 2 shows that relative survival is better for
Iowans diagnosed with prostate cancer when it is
confined to the prostate gland (local) or spread
slightly beyond the prostate (regional); indirect
evidence suggests that more prostate cancer has been
detected in this stage as a result of screening with
prostate specific antigen (PSA) followed by a digital
rectal exam (DRE). Five-year relative survival rates
for the 1990s compared to the 1980s has increased
20 percentage points for all stages and 13 percentage
points for local/regional disease. For patients
Figure 1 Prostate Cancer in Iowa, All Ages, 1973-2002
(Rates expressed per 100,000 males and age-adjusted to 2000 U.S. population)
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7diagnosed with local/regional prostate cancer
between 1992 and 1999, the relative survival rate was
103 percent. The relative survival rate is commonly
used when comparing survival between populations
over time. It is the ratio of the observed survival
divided by the survival that would have been expected
if these patients had experienced only the mortality
of the general population of the United States.
A relative survival rate in excess of 100 percent
provides support for the hypothesis that PSA is
being administered to men who have a longer life
expectancy.
From 1990-92 compared with 2000-02, the Iowa
Cancer Registry database shows that localized and
regional disease has increased from 73% to 91%,
respectively. Distant stage decreased from 12% to 5%.
Unstaged prostate cases decreased from 16% to 4%.
These findings were similar for the age groups <65,
65-74, and 75-84 but the improvement was not as
dramatic in the 85+ age group. Here, 66% of cases
were localized or regional in 2000-02 and 34% were
still distant or unstaged.
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In Table 1 (see page 6) between 1990-92 and 2000-02,
the rate of newly diagnosed prostate cancers in Iowa
men under the age of 65 increased from 29.4 per
100,000 to 49.9 per 100,000, an increase of 70%.
During the same periods, these rates remained stable
in the 65–74 age group and declined 39 and 48
percent, respectively, in the 75–84 and 85+ age groups.
There has also been a shift in the age at diagnosis to
where in 2000-02, 29% of prostate cancers were
diagnosed under the age of 65 compared with 15% in
1990-92. These findings could be explained by more
selective use of PSA screening today that more often
takes into account life expectancy.
Between 1990-92 and 2000-02, the prostate cancer
death rate has declined around 30% in the <65, 65-74,
and 75-84 age groups, but declined much less in the
85+ age group. This correlates with the stage shift
information and supports the hypothesis that PSA
screening has led to earlier diagnosis of prostate
cancer and a decreased likelihood of death, particu-
larly under age 85.
5
Figure 2 Five-Year Relative Survival Rates for Prostate Cancer, All Ages, Iowa
8Outcome Age Group in Years                       Time Period         % Change
1990-92 2000-02 2000-02 vs. 1990-92
Newly diagnosed < 65 29.4 (1046) 49.9 (1946) +69.7
65 - 74 944.9 (2868) 911.7 (2598)   -3.5
75 – 84 1502.9 (2483) 914.5 (1731) -39.2
85+ 1568.7   (695) 816.2   (460) -48.0
Underlying cause of death < 65 2.3   (82) 1.3   (52) -43.5
65 – 74 113.0 (343) 79.6 (226) -29.6
75 – 84 351.7 (581) 265.3 (506) -24.6
85+ 783.2 (347) 697.9 (398) -10.9
Table 1 Prostate Cancer Age-specific Rates (number) by Time Period, Iowa
The natural history of prostate cancer is poorly
understood, and it is difficult to determine clinically
significant prostate cancer when it is confined to the
prostate gland. The general absence of modifiable risk
factors for prostate cancer precludes any effective
primary prevention at this time. Secondary prevention
to reduce mortality through screening and early
detection remains controversial. Three potential
screening tests for prostate cancer include the digital
rectal exam (DRE), prostate specific antigen (PSA),
and transrectal ultrasound (TRUS). TRUS can be a
useful diagnostic test when used in conjunction with
DRE and PSA, but it is not recommended as an
independent screening test. Randomized clinical trials
of the benefits of DRE and PSA screening are under
way, but the results are not yet available. The United
States Preventive Services Task Force and the National
Cancer Institute make no recommendations for
routine screening with either DRE or PSA; however,
the American Cancer Society recommends annual
DRE and PSA testing beginning at age 50 for those
who have at least a 10-year life expectancy, and for
younger men who are at high risk.
While there is controversy regarding screening for
prostate cancer in general, there are no norms for
screening in the older patients whose life expectancy
is less than 10 years. Data from large studies indicate
that the rate of PSA-based screening for prostate
cancer in men 75 years of age is still fairly high and
occurs at a rate higher than colorectal cancer screen-
ing for fecal occult blood. Indiscriminate use of
screening practices can result in significant cost and
potential morbidity to these older men from interven-
tions performed to evaluate abnormal screening tests
or unnecessary treatment of diagnosed prostate
cancer. On the other hand, appropriate and judicious
use of screening practices may be necessary even
in elderly men if there is increased suspicion
of symptomatic prostate cancer or if the life expect-
ancy is obviously >10 years such that these men will
benefit from local radiation or hormonal therapy. 
The Iowa Consortium for Comprehensive Cancer
Control (visit their website at www.canceriowa.org)
and the University of Iowa are collaborating on a
project funded through the Centers for Disease
Control aimed at assessing physician practice
approaches to screening for prostate cancer and
developing a more standardized approach to the care
of older men with prostate cancer. As part of this
project, a survey of all providers in Iowa will be
conducted this year to determine prevailing
approaches towards screening for and managing
prostate cancer in men over 75 years of age. 
A multidisciplinary committee including physicians
from various specialties will be constituted to develop
a set of recommendations to guide the management
of older men with prostate cancer.  This will be
followed by a repeat survey and audit to determine
the effectiveness of this approach in better standard-
izing prostate cancer screening, diagnosis and
treatment in these older men.
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9Research Projects During 2005
The State Health Registry of Iowa is participating in
over two dozen funded studies during 2005. Brief
descriptions of a few of these studies are provided.
The Agricultural Health Study
The Agricultural Health Study is a long-term study of
agricultural exposures and chronic disease (especially
cancer) among commercial or private pesticide
applicators (and their spouses, if married) in Iowa
and North Carolina. The study is funded primarily by
the National Cancer Institute. We are in the 13th year
of the study, which received renewed funding at the
end of 2003 for continuation through 2008.
In the first five years, 89,658 subjects (58,564 in Iowa
and 31,094 in North Carolina) were enrolled in the
study. This total for Iowa included 31,877 private
applicators, 21,771 spouses of private applicators,
and 4,916 commercial applicators. Enrollment con-
sisted of completing questionnaires about past
exposures and health. The second phase of the study
for private applicators and their spouses was
completed at the end of 2003. It involved a telephone
interview, a mailed dietary questionnaire, and
collection of a cheek cell sample from all consenting
cohort members. The telephone interview asked
about pesticide use since enrollment, current farming
and work practices, and health changes. The dietary
health questionnaire asked about cooking practices
and types of foods eaten. Cooking practices and diet
may play a role in cancer and other health conditions.
The cheek cells will be used to understand possible
links between genetics, exposures, and disease. The
second phase of the study is ongoing with commercial
applicators. Pilot testing for the study’s third phase
began at the end of 2004 and involves updating
information about exposures and health.
Since 1997, personal-identifying information provided
by cohort members has been linked annually to
mortality and cancer registry incidence databases in
both states. In addition, mortality data on the cohort
are being obtained from the National Death Index.
More information about recent results from this
study, the study background, frequently asked
questions, other resources (internet & telephone)
for agricultural health information, references for
publications to date, and information for scientific
collaborators can be found at the website,
www.aghealth.org. Here publications are organized
under the following subtitles: methods, exposure
assessment, high pesticide exposure events,
environmental measures, health outcomes, and diet.
The abstract and/or full text is available for these
publications at the website.
Breast Cancer, Radiation Exposure, and Genetic
Susceptibility
The objective of this study is to investigate gene-
environment interactions in the etiology of breast
cancer. We have established a repository of epidemio-
logic risk factor information and biologic specimens
for about 700 women with asynchronous bilateral
breast cancer (cases) and 1400 women with unilateral
breast cancer (controls), who were ascertained
through 5 population-based tumor registries in the
U.S. and Denmark, including the State Health Registry
of Iowa. All subjects were interviewed using a
structured questionnaire and blood samples were
collected for genetic analyses. Currently, we are
examining the ataxia-telangiectasia mutated (ATM)
gene, and breast cancer. Ionizing radiation is known
to be a breast carcinogen and recent studies suggest
that the ATM gene may increase susceptibility to
radiation-induced breast cancer. Our hypothesis is
that women who are ATM gene carriers and who have
received radiation therapy as part of breast cancer
treatment are at an increased risk of developing a
second primary breast cancer. The study is providing
descriptive statistics on the prevalence of ATM in this
large population-based sample of women. Collected
7
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or the combination of follicular and small lymphocytic
lymphoma. To achieve these aims, we are developing
a prognostic cohort that entails medical record review
from a case-control study that involved 364 HIV-
negative NHL patients in Iowa newly diagnosed from
July 1, 1998 to June 30, 2000.
Second Cancer Studies of Gastrointestinal (GI)
System
The Second GI Cancer Study includes seven case-
control investigations with a common primary
purpose of evaluating the relation between cancer
treatment (radiation and/or chemotherapy) and
cancer risk for three gastrointestinal organs (stomach,
pancreas, esophagus). Radiation and chemotherapy
are commonly used as treatment for the cancers in
this series (Hodgkin disease and cancer of the testis,
breast and cervix). Radiation and chemotherapy may
be given with the intention of curing cancer or for
cancer control and prolonged life. The cumulative
effect may include a risk of developing treatment-
induced cancers. The results of this series of studies
will help determine if current treatment protocols
should be modified to control the risk of second
cancers involving the stomach, pancreas, or
esophagus. Through 2004, the State Health Registry
completed detailed radiation and chemotherapy
data collection forms for 72 of its anticipated 99
eligible cancer patients in this collaborative
international study.
A GIS Based Workbench to Interpret Cancer Maps
This research is developing and testing a methodology
for identifying regions of excess cancer burden for
breast and colorectal cancer in Iowa. It will refine
measures of geographic access to cancer prevention,
treatment and screening services in Iowa by comput-
ing values using fine-scaled geographic data on
individuals, the spatial choices of individuals and the
locations of service providers. It uses State Health
8
data are also being used to determine the prevalence
of BRCA1 and BRCA2 mutations in this population and
evaluate interactions between breast cancer, BRCA1/2
and ATM genetic mutations, and radiation exposure.
Iowa contributed questionnaire data and blood
samples for 113 cases and 253 controls.
Lung Cancer Care Outcomes/Surveillance
Consortium
This study involves a coordinating center, the State
Health Registry of Iowa, and six other research sites
across the United States. Across these sites, we are
investigating patterns of care for lung cancer, the
reasons for particular care decisions by patients and
their physicians, variation in dissemination of modern
care protocols and practices in different geographic
areas, and the effects of these decisions and practices
on patient outcomes, including quality of life.
Through 2004, we have enrolled 565 lung cancer
patients in Iowa who were newly diagnosed since
June 2003. Study enrollment is planned to continue
with cases diagnosed through January 2005 as we seek
our goal of enrolling 1,000 patients.
Immunogenetic Determinants of Non-Hodgkin
Lymphoma (NHL) Survival
In this study we are collaborating with researchers at
the Mayo Clinic to investigate whether genes with
functional, common variant polymorphisms involved
in immune function and regulation are associated
with overall survival from NHL. The specific aims are
to evaluate: 1) the association of polymorphisms in
selected immune-related genes from four key path-
ways on NHL survival that include genes encoding
inflammatory and regulatory cytokines, Th1/Th2
cytokines, innate immunity, and chemokines;
2) whether any effects are independent of other
established NHL prognostic factors (such as age and
stage) and treatment modalities; and 3) whether any
effects are specific to diffuse large B-cell lymphoma
11
Registry of Iowa data for a thirteen-year period and
links patient files to Medicare and selected medical
insurance records. Statistical models are being
computed to associate specific cancer burden
measures to predictor variables that capture local
characteristics of the area and characteristics of the
individuals. A regional simulation workbench is being
developed to generate the expected range and
variations in the cancer burden measures for small
geographic areas of Iowa based on local demographic
characteristics of the area and statewide cancer
burden rates. Results can be used to plan more
appropriate cancer prevention and control programs.
SEER Patterns of Care Studies
This is a collaborative set of studies between the
National Cancer Institute and its 14 SEER Registries.
In 2005, these studies will investigate state-of-the-art
therapies for bladder cancer, chronic myelogenous
leukemia, myeloma, and B-cell lymphoma. Across
these cancer sites, 235 patients will be eligible at the
State Health Registry of Iowa and each will have been
newly diagnosed during 2003.
Cooperative Agreements and Other Registries
The SHRI maintains cooperative agreements with
several hospital cancer registries and other agencies/
entities. Some of the latter include:
• Iowa Department of Public Health
• The University of Iowa
- Center for Health Effects of Environmental
Contamination
- Center for Public Health Statistics
- Environmental Health Sciences Research Center
- Health Effectiveness Research Center
- Holden Comprehensive Cancer Center
- Iowa Center for Agricultural Safety and Health
- Injury Prevention Research Center
- Prevention Intervention Center
- Reproductive Molecular Epidemiology Research
& Education Program
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